Business Description
BriaCell Therapeutics Corp
NAICS : 325414
SIC : 3741
ISIN : CA10778Y1043
Share Class Description:
TSX:BCT: Ordinary Shares - NewCompare
Compare
Traded in other countries / regions
BCT.CanadaBCTX.USA8BT.Germany IPO Date
2006-10-12Description
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | -0.41 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 10 | |||||
| 3-Year EPS without NRI Growth Rate | -12 | |||||
| 3-Year FCF Growth Rate | 1.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 32.01 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.06 | |||||
| 9-Day RSI | 36.96 | |||||
| 14-Day RSI | 41.9 | |||||
| 3-1 Month Momentum % | 9.09 | |||||
| 6-1 Month Momentum % | -54.35 | |||||
| 12-1 Month Momentum % | -84.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.49 | |||||
| Quick Ratio | 0.49 | |||||
| Cash Ratio | 0.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.2 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -33.11 | |||||
| ROIC % | -1293.33 | |||||
| 3-Year ROIIC % | -1352.34 | |||||
| ROC (Joel Greenblatt) % | -1517.7 | |||||
| ROCE % | -344.78 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.73 | |||||
| EV-to-Forward-EBIT | -0.79 | |||||
| EV-to-EBITDA | -0.74 | |||||
| EV-to-FCF | -1.01 | |||||
| Earnings Yield (Greenblatt) % | -137.01 | |||||
| FCF Yield % | -95.22 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BriaCell Therapeutics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | |||
| EPS (TTM) (C$) | -1.585 | ||
| Beta | 2.38 | ||
| 3-Year Sharpe Ratio | -0.49 | ||
| 3-Year Sortino Ratio | -0.71 | ||
| Volatility % | 92.37 | ||
| 14-Day RSI | 41.9 | ||
| 14-Day ATR (C$) | 0.211965 | ||
| 20-Day SMA (C$) | 1.219 | ||
| 12-1 Month Momentum % | -84.64 | ||
| 52-Week Range (C$) | 0.64 - 8 | ||
| Shares Outstanding (Mil) | 36.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BriaCell Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BriaCell Therapeutics Corp Stock Events
| Event | Date | Price (C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
BriaCell Therapeutics Corp Frequently Asked Questions
What is BriaCell Therapeutics Corp(TSX:BCT)'s stock price today?
The current price of TSX:BCT is C$0.95. The 52 week high of TSX:BCT is C$8.00 and 52 week low is C$0.64.
When is next earnings date of BriaCell Therapeutics Corp(TSX:BCT)?
The next earnings date of BriaCell Therapeutics Corp(TSX:BCT) is 2025-03-18 Est..
Does BriaCell Therapeutics Corp(TSX:BCT) pay dividends? If so, how much?
BriaCell Therapeutics Corp(TSX:BCT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers